blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2640699

EP2640699 - BRIDGED SPIRO[2,4]HEPTANE ESTER DERIVATIVES [Right-click to bookmark this link]
Former [2013/39]BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES
[2015/18]
StatusNo opposition filed within time limit
Status updated on  12.08.2016
Database last updated on 20.07.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Actelion Pharmaceuticals Ltd.
Gewerbestrasse 16
4123 Allschwil / CH
[2013/39]
Inventor(s)01 / BUR, Daniel
c/o Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
4123 Allschwil / CH
02 / CORMINBOEUF, Olivier
c/o Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
4123 Allschwil / CH
03 / CREN, Sylvaine
c/o Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
4123 Allschwil / CH
04 / GRISOSTOMI, Corinna
c/o Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
4123 Allschwil / CH
05 / LEROY, Xavier
c/o Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
4123 Allschwil / CH
06 / POZZI, Davide
c/o Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
4123 Allschwil / CH
07 / RICHARD-BILDSTEIN, Sylvia
c/o Actelion PharmaceuticalsLtd
Gewerbestrasse 16
4123 Allschwil / CH
 [2013/39]
Representative(s)Gschwend, Thomas Peter
Actelion Pharmaceuticals Ltd.
Legal Department
Gewerbestrasse 16
4123 Allschwil / CH
[2015/41]
Former [2013/39]Gschwend, Thomas Peter
Actelion Pharmaceuticals Ltd. Legal Department Gewerbestrasse 16
4123 Allschwil / CH
Application number, filing date11824274.216.11.2011
[2015/41]
WO2011IB55125
Priority number, dateWO2010IB5523117.11.2010         Original published format: PCT/IB2010/055231
[2013/39]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012066488
Date:24.05.2012
Language:EN
[2012/21]
Type: A2 Application without search report 
No.:EP2640699
Date:25.09.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 24.05.2012 takes the place of the publication of the European patent application.
[2013/39]
Type: B1 Patent specification 
No.:EP2640699
Date:07.10.2015
Language:EN
[2015/41]
Search report(s)International search report - published on:EP26.07.2012
ClassificationIPC:C07D213/75, C07D401/12, C07D413/12, C07D261/08, C07D207/10, C07D295/088, C07D211/42, A61K31/4465, A61P29/00
[2015/18]
CPC:
C07D263/32 (EP,US); C07D401/12 (EP,KR,US); A61K31/444 (KR);
A61P11/08 (EP); A61P25/00 (EP); A61P25/04 (EP);
A61P25/28 (EP); A61P29/00 (EP); A61P31/18 (EP);
A61P37/02 (EP); A61P37/08 (EP); A61P9/00 (EP);
C07C69/753 (EP,US); C07D205/04 (EP,US); C07D207/08 (EP,US);
C07D207/10 (EP,US); C07D207/12 (EP,US); C07D211/14 (EP,US);
C07D211/22 (EP,US); C07D211/42 (EP,US); C07D213/75 (EP,US);
C07D241/04 (EP,US); C07D261/08 (EP,US); C07D295/088 (EP,US);
C07D413/12 (EP,US) (-)
Former IPC [2013/39]C07D211/22
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/39]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VEBRÜCKTE SPIRO[2,4]HEPTANESTER-DERIVATE[2015/18]
English:BRIDGED SPIRO[2,4]HEPTANE ESTER DERIVATIVES[2015/18]
French:DÉRIVÉS D'ESTERS DE SPIRO[2.4]HEPTANE PONTÉS[2015/18]
Former [2013/39]GEBRÜCKTE SPIRO-[2,4-]HEPTANESTERDERIVATE
Former [2013/39]BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES
Former [2013/39]DÉRIVÉS À PONTS ESTER DE SPIRO [2.4]HEPTANE
Entry into regional phase17.06.2013National basic fee paid 
17.06.2013Designation fee(s) paid 
17.06.2013Examination fee paid 
Examination procedure17.06.2013Examination requested  [2013/39]
03.07.2014Despatch of a communication from the examining division (Time limit: M06)
27.11.2014Reply to a communication from the examining division
24.04.2015Communication of intention to grant the patent
20.08.2015Fee for grant paid
20.08.2015Fee for publishing/printing paid
20.08.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.07.2014
Opposition(s)08.07.2016No opposition filed within time limit [2016/37]
Fees paidRenewal fee
02.12.2013Renewal fee patent year 03
01.12.2014Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.11.2011
AL07.10.2015
AT07.10.2015
BE07.10.2015
BG07.10.2015
CY07.10.2015
CZ07.10.2015
DK07.10.2015
EE07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
MK07.10.2015
MT07.10.2015
NL07.10.2015
PL07.10.2015
RO07.10.2015
RS07.10.2015
SE07.10.2015
SI07.10.2015
SK07.10.2015
SM07.10.2015
TR07.10.2015
IE16.11.2015
LU16.11.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
[2018/46]
Former [2018/31]HU16.11.2011
AT07.10.2015
BE07.10.2015
BG07.10.2015
CY07.10.2015
CZ07.10.2015
DK07.10.2015
EE07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
MK07.10.2015
MT07.10.2015
NL07.10.2015
PL07.10.2015
RO07.10.2015
RS07.10.2015
SE07.10.2015
SI07.10.2015
SK07.10.2015
SM07.10.2015
TR07.10.2015
IE16.11.2015
LU16.11.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2018/02]HU16.11.2011
AT07.10.2015
BE07.10.2015
BG07.10.2015
CY07.10.2015
CZ07.10.2015
DK07.10.2015
EE07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
MT07.10.2015
NL07.10.2015
PL07.10.2015
RO07.10.2015
RS07.10.2015
SE07.10.2015
SI07.10.2015
SK07.10.2015
SM07.10.2015
IE16.11.2015
LU16.11.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2017/39]HU16.11.2011
AT07.10.2015
BE07.10.2015
BG07.10.2015
CY07.10.2015
CZ07.10.2015
DK07.10.2015
EE07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
MT07.10.2015
NL07.10.2015
PL07.10.2015
RO07.10.2015
RS07.10.2015
SE07.10.2015
SI07.10.2015
SK07.10.2015
SM07.10.2015
IE16.11.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2017/03]AT07.10.2015
BE07.10.2015
CZ07.10.2015
DK07.10.2015
EE07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
NL07.10.2015
PL07.10.2015
RO07.10.2015
RS07.10.2015
SE07.10.2015
SI07.10.2015
SK07.10.2015
SM07.10.2015
IE16.11.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2016/49]AT07.10.2015
CZ07.10.2015
DK07.10.2015
EE07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
NL07.10.2015
PL07.10.2015
RO07.10.2015
RS07.10.2015
SE07.10.2015
SI07.10.2015
SK07.10.2015
SM07.10.2015
IE16.11.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2016/45]AT07.10.2015
CZ07.10.2015
DK07.10.2015
EE07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
NL07.10.2015
PL07.10.2015
RO07.10.2015
RS07.10.2015
SE07.10.2015
SK07.10.2015
SM07.10.2015
IE16.11.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2016/39]AT07.10.2015
CZ07.10.2015
DK07.10.2015
EE07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
NL07.10.2015
PL07.10.2015
RO07.10.2015
RS07.10.2015
SE07.10.2015
SK07.10.2015
SM07.10.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2016/38]AT07.10.2015
CZ07.10.2015
EE07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
NL07.10.2015
PL07.10.2015
RO07.10.2015
RS07.10.2015
SE07.10.2015
SK07.10.2015
SM07.10.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2016/36]AT07.10.2015
CZ07.10.2015
EE07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
NL07.10.2015
PL07.10.2015
RO07.10.2015
RS07.10.2015
SE07.10.2015
SK07.10.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2016/34]AT07.10.2015
CZ07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
NL07.10.2015
PL07.10.2015
RS07.10.2015
SE07.10.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2016/33]AT07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
MC07.10.2015
NL07.10.2015
PL07.10.2015
RS07.10.2015
SE07.10.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2016/25]AT07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
LV07.10.2015
NL07.10.2015
PL07.10.2015
RS07.10.2015
SE07.10.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2016/24]AT07.10.2015
FI07.10.2015
HR07.10.2015
LT07.10.2015
NL07.10.2015
PL07.10.2015
RS07.10.2015
SE07.10.2015
NO07.01.2016
GR08.01.2016
IS07.02.2016
PT08.02.2016
Former [2016/23]HR07.10.2015
LT07.10.2015
NL07.10.2015
RS07.10.2015
SE07.10.2015
NO07.01.2016
IS07.02.2016
Former [2016/22]LT07.10.2015
NL07.10.2015
NO07.01.2016
IS07.02.2016
Former [2016/21]LT07.10.2015
NO07.01.2016
Former [2016/20]LT07.10.2015
Cited inInternational search[XDP]WO2010134014  (ACTELION PHARMACEUTICALS LTD [CH], et al) [XDP] 1-15 * page 79, Structure 2; page 83, structure 2; page 87, enantiopure structure 2; page 107, lines 1-2; page 109, lines 1-2; pages 152-157; claim 1 *;
 [E]WO2011163502  (ALLERGAN INC [US], et al) [E] 1-15 * claims 1,12,13; compounds 17,18 *
 [A]  - B. S. EDWARDS, "Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonists", MOLECULAR PHARMACOLOGY, (20050812), vol. 68, no. 5, doi:10.1124/mol.105.014068, ISSN 0026-895X, pages 1301 - 1310, XP055026266 [A] 1-15 * Figure 3, Group F *

DOI:   http://dx.doi.org/10.1124/mol.105.014068
Examination   - PATANI G A ET AL, "BIOISOSTERISM: A RATIONAL APPROACH IN DRUG DESIGN", CHEMICAL REVIEWS, AMERICAN CHEMICAL SOCIETY, US, (19960101), vol. 96, no. 8, doi:10.1021/CR950066Q, ISSN 0009-2665, pages 3147 - 3176, XP000652176

DOI:   http://dx.doi.org/10.1021/cr950066q
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.